• 1. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 2. Fate of single walled carbon nanotubes in wetland ecosystems?
  Joseph H. Bisesi,Tara Sabo-Attwood Environ. Sci.: Nano, 2014,1, 574-583
• 3. Evolution in surface coverage of CH3NH3PbI3?XClXvia heat assisted solvent vapour treatment and their effects on photovoltaic performance of devices
  Dhirendra K. Chaudhary,Pramendra Kumar,Lokendra Kumar RSC Adv., 2016,6, 94731-94738
• 4. Dissociative dynamics of O2 on Ag(110)?
  Ivor Lon?ari? Phys. Chem. Chem. Phys., 2015,17, 9436-9445
• 5. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739

Professional Introduction to 4-Iodo-1-trityl-1H-pyrazole (CAS No. 191980-54-8)

4-Iodo-1-trityl-1H-pyrazole, identified by its Chemical Abstracts Service (CAS) number 191980-54-8, is a specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This heterocyclic compound features a pyrazole core substituted with an iodo group at the 4-position and a trityl (triphenylmethyl) group at the 1-position, making it a versatile intermediate in the synthesis of biologically active molecules.

The structural configuration of 4-Iodo-1-trityl-1H-pyrazole imparts unique reactivity, enabling its utility in various synthetic transformations. The presence of the iodo substituent facilitates nucleophilic aromatic substitution reactions, while the trityl group provides stability and handles during multi-step syntheses. These characteristics make it a valuable building block for constructing complex pharmaceutical scaffolds.

In recent years, 4-Iodo-1-trityl-1H-pyrazole has been explored in the development of novel therapeutic agents. Its pyrazole moiety is a privileged scaffold in drug discovery, known for its role in molecules targeting inflammatory diseases, cancer, and infectious disorders. For instance, studies have demonstrated its potential in generating derivatives with inhibitory activity against enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX), which are implicated in pain and inflammation pathways.

Moreover, the compound has been utilized in the synthesis of small-molecule inhibitors targeting protein-protein interactions. The pyrazole ring can serve as a hinge-binding motif, interacting with specific residues in protein targets to modulate their function. This aspect has been particularly relevant in the design of kinase inhibitors, which are critical in oncology therapy. Recent advancements in computational chemistry have further optimized the use of 4-Iodo-1-trityl-1H-pyrazole as a precursor for structure-based drug design, leveraging molecular docking simulations to predict binding affinities and optimize lead compounds.

The trityl group in 4-Iodo-1-trityl-1H-pyrazole not only enhances synthetic manipulability but also contributes to the compound's pharmacokinetic properties. Tritylated compounds often exhibit improved solubility and stability, which are essential for formulation development. This has led to its incorporation in libraries of compounds screened for drug-like properties, where physicochemical parameters such as lipophilicity and solubility are carefully evaluated.

Recent research has also highlighted the role of halogenated pyrazoles in medicinal chemistry. The iodo substituent at the 4-position of 4-Iodo-1-trityl-1H-pyrazole allows for further functionalization via cross-coupling reactions such as Suzuki-Miyaura or Stille couplings. These reactions enable the introduction of aryl or vinyl groups, expanding the structural diversity of derived compounds. Such modifications have been instrumental in generating novel analogs with enhanced biological activity or reduced toxicity profiles.

In clinical trials and preclinical studies, derivatives of 4-Iodo-1-trityl-1H-pyrazole have shown promise as antiviral and antibacterial agents. The pyrazole core disrupts essential metabolic pathways in pathogens, while the iodo and trityl groups influence metabolic stability and bioavailability. For example, researchers have synthesized analogs with activity against herpesviruses by incorporating additional substituents that enhance binding to viral enzymes.

The synthesis of 4-Iodo-1-trityl-1H-pyrazole itself is a testament to modern synthetic methodologies. Advances in transition-metal catalysis have streamlined its preparation from commercially available precursors, reducing reaction times and improving yields. This accessibility has democratized its use among academic and industrial researchers alike, fostering innovation across multiple therapeutic areas.

Future directions in the study of 4-Iodo-1-trityl-1H-pyrazole may explore its role in photodynamic therapy or as a probe for enzyme mechanisms. The compound's ability to undergo photochemical transformations under controlled conditions opens avenues for developing novel therapeutic strategies that combine phototherapy with traditional drug delivery systems.

In conclusion, 4-Iodo-1-trityl-1H-pyrazole (CAS No. 191980-54-8) represents a cornerstone molecule in contemporary pharmaceutical research. Its unique structural features and reactivity profile make it indispensable for designing next-generation therapeutics targeting diverse diseases. As synthetic chemistry continues to evolve, compounds like this will remain pivotal in advancing drug discovery efforts worldwide.

• 760992-12-9(1H-Pyrazole, 1-[bis(4-methoxyphenyl)methyl]-4-iodo-)
• 60629-22-3(1H-PYRAZOLE, 1-([1,1'-BIPHENYL]-4-YLPHENYLMETHYL)-)
• 101974-12-3(2H-Indazole, 2-(triphenylmethyl)-)
• 95163-43-2(1-Trityl-1H-pyrazole)
• 50877-42-4(1-benzyl-4-iodo-pyrazole)
• 95162-14-4(4-Bromo-1-trityl-1H-pyrazole)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)